Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665327 · ClinicalTrials.gov registry record · Phase 4
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 401
- Enrollment target
NCT00665327 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 401 participants.
The verdict
NCT00665327, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 401 participants
- Enrollment target
Study Summary
This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged \≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This study also included an assessment of the clinical and bacteriologic effectiveness of both drugs.
Interventions
- DRUG Levofloxacin
- DRUG Avelox (Moxifloxacin, BAY12-8039)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665327
The ClinicalTrials.gov registry entry for NCT00665327 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levofloxacin is the first listed.
NCT00665327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00665327 about?
NCT00665327 is a clinical study titled "Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia". This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged \≥ 65 years) with community-acquired pneumonia (CAP) who required initial IV therapy. This stud...
What is the current status of trial NCT00665327?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 401 participants. The study started on 2002-11. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00665327?
The interventions under investigation include: Levofloxacin (DRUG), Avelox (Moxifloxacin, BAY12-8039) (DRUG).
Who is sponsoring clinical trial NCT00665327?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.